Next-generation liposomal coenzyme Q₁₀: from formulation to clinical evidence via metazome technology for improved...

Coenzyme Q10 (CoQ₁₀) is a mitochondrial electron carrier and antioxidant widely used in cardiovascular, neurodegenerative, and metabolic disorders; however, its oral efficacy is severely limited by extremely low aqueous solubility, high crystallinity, and poor bioavailability. Although several lipid-based and nanoformulations have been explored, many suffer from limited stability, incomplete suppression of crystallinity, or modest pharmacokinetic improvement. The objective of this study was to develop a stable, scalable liposomal CoQ₁₀ formulation and to evaluate its physicochemical properties and human oral bioavailability. Metazomal CoQ₁₀ (MCQ) was developed using Metazome technology, in which CoQ₁₀ was incorporated into phospholipid bilayers reinforced with gum arabic nanospheres and converted into a dry, reconstitutable liposomal powder by spray drying. MCQ formed nanosized (∼185 nm), spherical vesicles with high encapsulation efficiency (88.6 ± 2.3%), favorable loading capacity (14.2 ± 0.8%), strong electrostatic stability (zeta potential -41.16 mV), and amorphous molecular dispersion of CoQ₁₀. The formulation retained >90% of CoQ₁₀ after 180 days at room temperature. In a randomized, open-label, crossover study in healthy volunteers, MCQ demonstrated significantly improved pharmacokinetics compared with conventional CoQ₁₀ (CCQ), including a 4.3-fold increase in AUC_0-t, a 3.6-fold increase in C_max, prolonged T_max, extended half-life, and a lower elimination rate constant (p < 0.01). The integrated Metazome-based architecture represents a key innovation by combining amorphization, nanoscale liposomal delivery, and structural stabilization, resulting in superior stability and markedly enhanced human bioavailability. MCQ therefore offers strong potential for nutraceutical and therapeutic applications requiring improved and sustained CoQ₁₀ exposure.